StockNews.com Begins Coverage on FibroGen (NASDAQ:FGEN)

Equities research analysts at StockNews.com initiated coverage on shares of FibroGen (NASDAQ:FGEN) in a research note issued to investors on Saturday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, William Blair restated a “market perform” rating on shares of FibroGen in a report on Wednesday, November 13th.

FibroGen Stock Performance

Shares of NASDAQ FGEN opened at $0.42 on Friday. FibroGen has a 52-week low of $0.18 and a 52-week high of $2.93. The stock has a market cap of $42.80 million, a P/E ratio of -0.35 and a beta of 0.72. The firm has a 50 day moving average price of $0.36 and a 200 day moving average price of $0.65.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.21. The firm had revenue of $46.33 million for the quarter, compared to the consensus estimate of $34.00 million. During the same period in the prior year, the business earned ($0.52) earnings per share. Analysts predict that FibroGen will post -0.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On FibroGen

Large investors have recently made changes to their positions in the stock. Point72 DIFC Ltd boosted its stake in FibroGen by 734.2% in the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 45,990 shares during the period. Doheny Asset Management CA acquired a new position in shares of FibroGen during the second quarter worth about $48,000. Accel Wealth Management grew its holdings in shares of FibroGen by 117.5% during the second quarter. Accel Wealth Management now owns 95,600 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 51,645 shares in the last quarter. Franklin Street Advisors Inc. NC bought a new position in shares of FibroGen during the second quarter worth about $89,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in FibroGen in the 2nd quarter valued at approximately $130,000. Institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.